Clinical Trial: Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population
Brief Summary: The aim of the study is to determine the efficacy and safety of treatment with the drug eplerenone in patients with chronic central serous chorioretinopathy.
Detailed Summary:
Sponsor: Semmelweis University
Current Primary Outcome:
- Resolution of sub-retinal fluid measured by optical coherence tomography (OCT). [ Time Frame: 6 months ]
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability. [ Time Frame: 3 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Changes in macular volume at baseline, during and after the treatment with eplerenone. [ Time Frame: 6 months ]
- Changes in visual acuity at baseline measured on Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, during and after the treatment with eplerenone. [ Time Frame: 6 months ]
- Changes in choroideal thickness at baseline measured by OCT, during and after the treatment with eplerenone in both eyes. [ Time Frame: 6 months ]
Original Secondary Outcome: Same as current
Information By: Semmelweis University
Dates:
Date Received: May 26, 2015
Date Started: June 2014
Date Completion:
Last Updated: October 15, 2016
Last Verified: October 2016